|
1
|
Bertolini P, Lassalle M, Mercier G, et al:
Platinum compound-related ototoxicity in children: long-term
follow-up reveals continuous worsening of hearing loss. J Pediatr
Hematol Oncol. 26:649–655. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Skinner R: Best practice in assessing
ototoxicity in children with cancer. Eur J Cancer. 40:2352–2354.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Orgel E, Jain S, Ji L, et al: Hearing loss
among survivors of childhood brain tumors treated with an
irradiation-sparing approach. Pediatr Blood Cancer. 58:953–958.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pecora Liberman PH, Schultz C, Schmidt
Goffi-Gomez MV, Antoneli CB, Motoro Chojniak M and Eduardo Novaes
P: Evaluation of ototoxicity in children treated for
retinoblastoma: preliminary results of a systematic audiological
evaluation. Clin Transl Oncol. 13:348–352. 2011.PubMed/NCBI
|
|
5
|
Stohr W, Langer T, Kremers A, et al:
Cisplatin-induced ototoxicity in osteosarcoma patients: a report
from the late effects surveillance system. Cancer Invest.
23:201–207. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bokemeyer C, Berger CC, Hartmann JT, et
al: Analysis of risk factors for cisplatin-induced ototoxicity in
patients with testicular cancer. Br J Cancer. 77:1355–1362. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brock PR, Bellman SC, Yeomans EC,
Pinkerton CR and Pritchard J: Cisplatin ototoxicity in children: a
practical grading system. Med Pediatr Oncol. 19:295–300. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ilveskoski I, Saarinen UM, Wiklund T, et
al: Ototoxicity in children with malignant brain tumors treated
with the ‘8 in 1’ chemotherapy protocol. Med Pediatr Oncol.
27:26–31. 1996.
|
|
9
|
Ruiz L, Gilden J, Jaffe N, Robertson R and
Wang YM: Auditory function in pediatric osteosarcoma patients
treated with multiple doses of cis-diamminedichloroplatinum(II).
Cancer Res. 49:742–744. 1989.PubMed/NCBI
|
|
10
|
Schell MJ, McHaney VA, Green AA, et al:
Hearing loss in children and young adults receiving cisplatin with
or without prior cranial irradiation. J Clin Oncol. 7:754–760.
1989.PubMed/NCBI
|
|
11
|
Reddel RR, Kefford RF, Grant JM, Coates
AS, Fox RM and Tattersall MH: Ototoxicity in patients receiving
cisplatin: importance of dose and method of drug administration.
Cancer Treat Rep. 66:19–23. 1982.PubMed/NCBI
|
|
12
|
Vermorken JB, Kapteijn TS, Hart AA and
Pinedo HM: Ototoxicity of cis-diamminedichloroplatinum (II):
influence of dose, schedule and mode of administration. Eur J
Cancer Clin Oncol. 19:53–58. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Macdonald MR, Harrison RV, Wake M, Bliss B
and Macdonald RE: Ototoxicity of carboplatin: comparing animal and
clinical models at the Hospital for Sick Children. J Otolaryngol.
23:151–159. 1994.PubMed/NCBI
|
|
14
|
Stohr W, Langer T, Kremers A, et al:
Hearing function in soft tissue sarcoma patients after treatment
with carboplatin: a report from the Late Effects Surveillance
System. Oncol Rep. 12:767–771. 2004.PubMed/NCBI
|
|
15
|
Parsons SK, Neault MW, Lehmann LE, et al:
Severe ototoxicity following carboplatin-containing conditioning
regimen for autologous marrow transplantation for neuroblastoma.
Bone Marrow Transplant. 22:669–674. 1998. View Article : Google Scholar
|
|
16
|
Langer T, Stöhr W, Paulides M, et al:
Prospective multicenter registration of major late sequelae in
sarcoma patients using the Late Effects Surveillance System (LESS).
Klin Padiatr. 217:176–181. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmidt CM, Bartholomäus E, Deuster D,
Heinecke A and Dinnesen AG: The ‘Muenster classification’ of high
frequency hearing loss following cisplatin chemotherapy. HNO.
55:299–306. 2007.(In German).
|
|
18
|
Einarsson EJ, Petersen H, Wiebe T, et al:
Long term hearing degeneration after platinum-based chemotherapy in
childhood. Int J Audiol. 49:765–771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lanvers-Kaminsky C, Krefeld B, Dinnesen
AG, et al: Continuous or repeated prolonged cisplatin infusions in
children: a prospective study on ototoxicity, platinum
concentrations, and standard serum parameters. Pediatr Blood
Cancer. 47:183–193. 2006. View Article : Google Scholar
|
|
20
|
Li Y, Womer RB and Silber JH: Predicting
cisplatin ototoxicity in children: the influence of age and the
cumulative dose. Eur J Cancer. 40:2445–2451. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Komune S, Asakuma S and Snow JB Jr:
Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum.
Otolaryngol Head Neck Surg. 89:275–282. 1981.PubMed/NCBI
|
|
22
|
Pickel VM, Beckley SC, Joh TH and Reis DJ:
Ultrastructural immunocytochemical localization of tyrosine
hydroxylase in the neostriatum. Brain Res. 225:373–385. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Musial-Bright L, Fengler R, Henze G and
Hernaiz Driever P: Carboplatin and ototoxicity: hearing loss rates
among survivors of childhood medulloblastoma. Childs Nerv Syst.
27:407–413. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Knight KR, Kraemer DF and Neuwelt EA:
Ototoxicity in children receiving platinum chemotherapy:
underestimating a commonly occurring toxicity that may influence
academic and social development. J Clin Oncol. 23:8588–8596. 2005.
View Article : Google Scholar
|
|
25
|
Kushner BH, Budnick A, Kramer K, Modak S
and Cheung NK: Ototoxicity from high-dose use of platinum compounds
in patients with neuroblastoma. Cancer. 107:417–422. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weatherly RA, Owens JJ, Catlin FI and
Mahoney DH: Cis-platinum ototoxicity in children. Laryngoscope.
101:917–924. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aguilar-Markulis NV, Beckley S, Priore R
and Mettlin C: Auditory toxicity effects of long-term
cis-dichlorodiammineplatinum II therapy in genitourinary cancer
patients. J Surg Oncol. 16:111–123. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Laurell G, Ekborn A, Viberg A and Canlon
B: Effects of a single high dose of cisplatin on the melanocytes of
the stria vascularis in the guinea pig. Audiol Neurootol.
12:170–178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marshall NE, Ballman KV, Michalak JC, et
al: Ototoxicity of cisplatin plus standard radiation therapy vs.
accelerated radiation therapy in glioblastoma patients. J
Neurooncol. 77:315–320. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Simon T, Hero B, Dupuis W, Selle B and
Berthold F: The incidence of hearing impairment after successful
treatment of neuroblastoma. Klin Padiatr. 214:149–152. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al-Khatib T, Cohen N, Carret AS and Daniel
S: Cisplatinum ototoxicity in children, long-term follow up. Int J
Pediatr Otorhinolaryngol. 74:913–919. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Laurell G and Jungnelius U: High-dose
cisplatin treatment: hearing loss and plasma concentrations.
Laryngoscope. 100:724–734. 1990. View Article : Google Scholar : PubMed/NCBI
|
